NL8120080A - Virusremmende stof en werkwijze voor de bereiding daarvan. - Google Patents

Virusremmende stof en werkwijze voor de bereiding daarvan. Download PDF

Info

Publication number: NL8120080A
Authority: NL; Netherlands
Prior art keywords: interferon; human; cells; epithelial cells; page
Prior art date: 1980-03-26

Application number

NL8120080A

Other languages

English (en)

Dutch (nl)

Inventor

Fumiaki Taguchi

Original Assignee

Fumiaki Taguchi

Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)

1980-03-26

Filing date

1981-03-25

Publication date

1982-02-01

1981-03-25 Application filed by Fumiaki Taguchi filed Critical Fumiaki Taguchi

1982-02-01 Publication of NL8120080A publication Critical patent/NL8120080A/nl

Links

238000000034 method Methods 0.000 title claims description 24
238000002360 preparation method Methods 0.000 title claims description 11
239000000126 substance Substances 0.000 title description 4
210000004027 cell Anatomy 0.000 claims description 95
102000014150 Interferons Human genes 0.000 claims description 83
108010050904 Interferons Proteins 0.000 claims description 83
229940079322 interferon Drugs 0.000 claims description 74
210000002919 epithelial cell Anatomy 0.000 claims description 44
241000700605 Viruses Species 0.000 claims description 30
210000002966 serum Anatomy 0.000 claims description 29
239000002609 medium Substances 0.000 claims description 24
230000000840 anti-viral effect Effects 0.000 claims description 18
210000002950 fibroblast Anatomy 0.000 claims description 16
239000001963 growth medium Substances 0.000 claims description 14
RAXXELZNTBOGNW-UHFFFAOYSA-N imidazole Natural products C1=CNC=N1 RAXXELZNTBOGNW-UHFFFAOYSA-N 0.000 claims description 12
238000011534 incubation Methods 0.000 claims description 11
SIKJAQJRHWYJAI-UHFFFAOYSA-N Indole Chemical compound C1=CC=C2NC=CC2=C1 SIKJAQJRHWYJAI-UHFFFAOYSA-N 0.000 claims description 10
NOESYZHRGYRDHS-UHFFFAOYSA-N insulin Chemical compound N1C(=O)C(NC(=O)C(CCC(N)=O)NC(=O)C(CCC(O)=O)NC(=O)C(C(C)C)NC(=O)C(NC(=O)CN)C(C)CC)CSSCC(C(NC(CO)C(=O)NC(CC(C)C)C(=O)NC(CC=2C=CC(O)=CC=2)C(=O)NC(CCC(N)=O)C(=O)NC(CC(C)C)C(=O)NC(CCC(O)=O)C(=O)NC(CC(N)=O)C(=O)NC(CC=2C=CC(O)=CC=2)C(=O)NC(CSSCC(NC(=O)C(C(C)C)NC(=O)C(CC(C)C)NC(=O)C(CC=2C=CC(O)=CC=2)NC(=O)C(CC(C)C)NC(=O)C(C)NC(=O)C(CCC(O)=O)NC(=O)C(C(C)C)NC(=O)C(CC(C)C)NC(=O)C(CC=2NC=NC=2)NC(=O)C(CO)NC(=O)CNC2=O)C(=O)NCC(=O)NC(CCC(O)=O)C(=O)NC(CCCNC(N)=N)C(=O)NCC(=O)NC(CC=3C=CC=CC=3)C(=O)NC(CC=3C=CC=CC=3)C(=O)NC(CC=3C=CC(O)=CC=3)C(=O)NC(C(C)O)C(=O)N3C(CCC3)C(=O)NC(CCCCN)C(=O)NC(C)C(O)=O)C(=O)NC(CC(N)=O)C(O)=O)=O)NC(=O)C(C(C)CC)NC(=O)C(CO)NC(=O)C(C(C)O)NC(=O)C1CSSCC2NC(=O)C(CC(C)C)NC(=O)C(NC(=O)C(CCC(N)=O)NC(=O)C(CC(N)=O)NC(=O)C(NC(=O)C(N)CC=1C=CC=CC=1)C(C)C)CC1=CN=CN1 NOESYZHRGYRDHS-UHFFFAOYSA-N 0.000 claims description 10
UJOBWOGCFQCDNV-UHFFFAOYSA-N 9H-carbazole Chemical compound C1=CC=C2C3=CC=CC=C3NC2=C1 UJOBWOGCFQCDNV-UHFFFAOYSA-N 0.000 claims description 8
HIMXGTXNXJYFGB-UHFFFAOYSA-N alloxan Chemical compound O=C1NC(=O)C(=O)C(=O)N1 HIMXGTXNXJYFGB-UHFFFAOYSA-N 0.000 claims description 8
244000309466 calf Species 0.000 claims description 7
SEOVTRFCIGRIMH-UHFFFAOYSA-N indole-3-acetic acid Chemical compound C1=CC=C2C(CC(=O)O)=CNC2=C1 SEOVTRFCIGRIMH-UHFFFAOYSA-N 0.000 claims description 6
210000004072 lung Anatomy 0.000 claims description 6
210000001161 mammalian embryo Anatomy 0.000 claims description 6
102000004877 Insulin Human genes 0.000 claims description 5
108090001061 Insulin Proteins 0.000 claims description 5
PZOUSPYUWWUPPK-UHFFFAOYSA-N indole Natural products CC1=CC=CC2=C1C=CN2 PZOUSPYUWWUPPK-UHFFFAOYSA-N 0.000 claims description 5
RKJUIXBNRJVNHR-UHFFFAOYSA-N indolenine Natural products C1=CC=C2CC=NC2=C1 RKJUIXBNRJVNHR-UHFFFAOYSA-N 0.000 claims description 5
229940125396 insulin Drugs 0.000 claims description 5
LRFVTYWOQMYALW-UHFFFAOYSA-N 9H-xanthine Chemical class O=C1NC(=O)NC2=C1NC=N2 LRFVTYWOQMYALW-UHFFFAOYSA-N 0.000 claims description 4
210000004381 amniotic fluid Anatomy 0.000 claims description 4
239000005712 elicitor Substances 0.000 claims description 4
210000000265 leukocyte Anatomy 0.000 claims description 4
DKNWSYNQZKUICI-UHFFFAOYSA-N amantadine Chemical compound C1C(C2)CC3CC2CC1(N)C3 DKNWSYNQZKUICI-UHFFFAOYSA-N 0.000 claims description 3
229960003805 amantadine Drugs 0.000 claims description 3
229940125717 barbiturate Drugs 0.000 claims description 3
HNYOPLTXPVRDBG-UHFFFAOYSA-N barbituric acid Chemical compound O=C1CC(=O)NC(=O)N1 HNYOPLTXPVRDBG-UHFFFAOYSA-N 0.000 claims description 3
239000003617 indole-3-acetic acid Substances 0.000 claims description 3
210000003734 kidney Anatomy 0.000 claims description 3
230000009257 reactivity Effects 0.000 claims description 3
210000003425 amniotic epithelial cell Anatomy 0.000 claims description 2
239000000960 hypophysis hormone Substances 0.000 claims description 2
239000004615 ingredient Substances 0.000 claims 1
210000001985 kidney epithelial cell Anatomy 0.000 claims 1
230000000694 effects Effects 0.000 description 35
210000001691 amnion Anatomy 0.000 description 21
229940047124 interferons Drugs 0.000 description 9
238000011282 treatment Methods 0.000 description 9
230000015572 biosynthetic process Effects 0.000 description 8
230000005764 inhibitory process Effects 0.000 description 8
239000000725 suspension Substances 0.000 description 8
HEMHJVSKTPXQMS-UHFFFAOYSA-M Sodium hydroxide Chemical compound [OH-].[Na+] HEMHJVSKTPXQMS-UHFFFAOYSA-M 0.000 description 6
238000007792 addition Methods 0.000 description 6
RYYVLZVUVIJVGH-UHFFFAOYSA-N caffeine Chemical compound CN1C(=O)N(C)C(=O)C2=C1N=CN2C RYYVLZVUVIJVGH-UHFFFAOYSA-N 0.000 description 6
238000010790 dilution Methods 0.000 description 6
239000012895 dilution Substances 0.000 description 6
208000015181 infectious disease Diseases 0.000 description 6
230000009467 reduction Effects 0.000 description 6
239000000243 solution Substances 0.000 description 6
239000013589 supplement Substances 0.000 description 6
239000000203 mixture Substances 0.000 description 5
239000006228 supernatant Substances 0.000 description 5
FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 description 4
102000004142 Trypsin Human genes 0.000 description 4
108090000631 Trypsin Proteins 0.000 description 4
230000000890 antigenic effect Effects 0.000 description 4
238000005119 centrifugation Methods 0.000 description 4
102000004169 proteins and genes Human genes 0.000 description 4
108090000623 proteins and genes Proteins 0.000 description 4
238000000746 purification Methods 0.000 description 4
239000000523 sample Substances 0.000 description 4
239000012588 trypsin Substances 0.000 description 4
230000009385 viral infection Effects 0.000 description 4
238000005406 washing Methods 0.000 description 4
QTBSBXVTEAMEQO-UHFFFAOYSA-N Acetic acid Chemical compound CC(O)=O QTBSBXVTEAMEQO-UHFFFAOYSA-N 0.000 description 3
LYCAIKOWRPUZTN-UHFFFAOYSA-N Ethylene glycol Chemical compound OCCO LYCAIKOWRPUZTN-UHFFFAOYSA-N 0.000 description 3
VEXZGXHMUGYJMC-UHFFFAOYSA-N Hydrochloric acid Chemical compound Cl VEXZGXHMUGYJMC-UHFFFAOYSA-N 0.000 description 3
102000002227 Interferon Type I Human genes 0.000 description 3
108010014726 Interferon Type I Proteins 0.000 description 3
LPHGQDQBBGAPDZ-UHFFFAOYSA-N Isocaffeine Natural products CN1C(=O)N(C)C(=O)C2=C1N(C)C=N2 LPHGQDQBBGAPDZ-UHFFFAOYSA-N 0.000 description 3
DBMJMQXJHONAFJ-UHFFFAOYSA-M Sodium laurylsulphate Chemical compound [Na+].CCCCCCCCCCCCOS([O-])(=O)=O DBMJMQXJHONAFJ-UHFFFAOYSA-M 0.000 description 3
230000009471 action Effects 0.000 description 3
229960001948 caffeine Drugs 0.000 description 3
VJEONQKOZGKCAK-UHFFFAOYSA-N caffeine Natural products CN1C(=O)N(C)C(=O)C2=C1C=CN2C VJEONQKOZGKCAK-UHFFFAOYSA-N 0.000 description 3
238000012258 culturing Methods 0.000 description 3
201000010099 disease Diseases 0.000 description 3
208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 3
210000005260 human cell Anatomy 0.000 description 3
238000006386 neutralization reaction Methods 0.000 description 3
241000894007 species Species 0.000 description 3
238000012360 testing method Methods 0.000 description 3
XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 3
FTOAOBMCPZCFFF-UHFFFAOYSA-N 5,5-diethylbarbituric acid Chemical compound CCC1(CC)C(=O)NC(=O)NC1=O FTOAOBMCPZCFFF-UHFFFAOYSA-N 0.000 description 2
241000894006 Bacteria Species 0.000 description 2
239000000055 Corticotropin-Releasing Hormone Substances 0.000 description 2
102000006992 Interferon-alpha Human genes 0.000 description 2
108010047761 Interferon-alpha Proteins 0.000 description 2
102000008070 Interferon-gamma Human genes 0.000 description 2
108010074328 Interferon-gamma Proteins 0.000 description 2
208000036142 Viral infection Diseases 0.000 description 2
238000003556 assay Methods 0.000 description 2
210000000601 blood cell Anatomy 0.000 description 2
201000011510 cancer Diseases 0.000 description 2
239000006285 cell suspension Substances 0.000 description 2
238000006243 chemical reaction Methods 0.000 description 2
IDLFZVILOHSSID-OVLDLUHVSA-N corticotropin Chemical compound C([C@@H](C(=O)N[C@@H](CO)C(=O)N[C@@H](CCSC)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](CC=1NC=NC=1)C(=O)N[C@@H](CC=1C=CC=CC=1)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CC=1C2=CC=CC=C2NC=1)C(=O)NCC(=O)N[C@@H](CCCCN)C(=O)N1[C@@H](CCC1)C(=O)N[C@@H](C(C)C)C(=O)NCC(=O)N[C@@H](CCCCN)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N1[C@@H](CCC1)C(=O)N[C@@H](C(C)C)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](C(C)C)C(=O)N[C@@H](CC=1C=CC(O)=CC=1)C(=O)N1[C@@H](CCC1)C(=O)N[C@@H](CC(N)=O)C(=O)NCC(=O)N[C@@H](C)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](CC(O)=O)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](CO)C(=O)N[C@@H](C)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](C)C(=O)N[C@@H](CC=1C=CC=CC=1)C(=O)N1[C@@H](CCC1)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](CC=1C=CC=CC=1)C(O)=O)NC(=O)[C@@H](N)CO)C1=CC=C(O)C=C1 IDLFZVILOHSSID-OVLDLUHVSA-N 0.000 description 2
229960000258 corticotropin Drugs 0.000 description 2
230000016396 cytokine production Effects 0.000 description 2
230000001747 exhibiting effect Effects 0.000 description 2
239000011521 glass Substances 0.000 description 2
230000012010 growth Effects 0.000 description 2
230000002401 inhibitory effect Effects 0.000 description 2
238000011081 inoculation Methods 0.000 description 2
238000004519 manufacturing process Methods 0.000 description 2
PGSADBUBUOPOJS-UHFFFAOYSA-N neutral red Chemical compound Cl.C1=C(C)C(N)=CC2=NC3=CC(N(C)C)=CC=C3N=C21 PGSADBUBUOPOJS-UHFFFAOYSA-N 0.000 description 2
239000004033 plastic Substances 0.000 description 2
239000011541 reaction mixture Substances 0.000 description 2
238000011160 research Methods 0.000 description 2
239000011780 sodium chloride Substances 0.000 description 2
238000001179 sorption measurement Methods 0.000 description 2
YAPQBXQYLJRXSA-UHFFFAOYSA-N theobromine Chemical compound CN1C(=O)NC(=O)C2=C1N=CN2C YAPQBXQYLJRXSA-UHFFFAOYSA-N 0.000 description 2
ZFXYFBGIUFBOJW-UHFFFAOYSA-N theophylline Chemical compound O=C1N(C)C(=O)N(C)C2=C1NC=N2 ZFXYFBGIUFBOJW-UHFFFAOYSA-N 0.000 description 2
229920001817 Agar Polymers 0.000 description 1
208000011691 Burkitt lymphomas Diseases 0.000 description 1
241000282693 Cercopithecidae Species 0.000 description 1
108010038061 Chymotrypsinogen Proteins 0.000 description 1
241000699800 Cricetinae Species 0.000 description 1
241000233866 Fungi Species 0.000 description 1
239000012981 Hank's balanced salt solution Substances 0.000 description 1
241000282412 Homo Species 0.000 description 1
101710186630 Insulin-1 Proteins 0.000 description 1
102000003996 Interferon-beta Human genes 0.000 description 1
108090000467 Interferon-beta Proteins 0.000 description 1
241001529936 Murinae Species 0.000 description 1
208000010359 Newcastle Disease Diseases 0.000 description 1
241000283973 Oryctolagus cuniculus Species 0.000 description 1
102000006877 Pituitary Hormones Human genes 0.000 description 1
108010047386 Pituitary Hormones Proteins 0.000 description 1
241000606651 Rickettsiales Species 0.000 description 1
229920005654 Sephadex Polymers 0.000 description 1
239000012507 Sephadex™ Substances 0.000 description 1
239000000654 additive Substances 0.000 description 1
239000008272 agar Substances 0.000 description 1
150000001413 amino acids Chemical class 0.000 description 1
239000000427 antigen Substances 0.000 description 1
102000036639 antigens Human genes 0.000 description 1
108091007433 antigens Proteins 0.000 description 1
229960002319 barbital Drugs 0.000 description 1
230000008901 benefit Effects 0.000 description 1
210000000941 bile Anatomy 0.000 description 1
150000001720 carbohydrates Chemical class 0.000 description 1
238000012512 characterization method Methods 0.000 description 1
210000003837 chick embryo Anatomy 0.000 description 1
238000004440 column chromatography Methods 0.000 description 1
238000001816 cooling Methods 0.000 description 1
238000011161 development Methods 0.000 description 1
238000002405 diagnostic procedure Methods 0.000 description 1
239000003085 diluting agent Substances 0.000 description 1
239000006185 dispersion Substances 0.000 description 1
239000003814 drug Substances 0.000 description 1
238000001962 electrophoresis Methods 0.000 description 1
238000010828 elution Methods 0.000 description 1
210000002257 embryonic structure Anatomy 0.000 description 1
230000002708 enhancing effect Effects 0.000 description 1
210000000981 epithelium Anatomy 0.000 description 1
-1 etc. Chemical compound 0.000 description 1
238000002474 experimental method Methods 0.000 description 1
239000012530 fluid Substances 0.000 description 1
210000003953 foreskin Anatomy 0.000 description 1
239000012520 frozen sample Substances 0.000 description 1
238000002523 gelfiltration Methods 0.000 description 1
150000004676 glycans Chemical class 0.000 description 1
238000000338 in vitro Methods 0.000 description 1
238000001727 in vivo Methods 0.000 description 1
230000002779 inactivation Effects 0.000 description 1
230000002458 infectious effect Effects 0.000 description 1
206010022000 influenza Diseases 0.000 description 1
239000003112 inhibitor Substances 0.000 description 1
238000011835 investigation Methods 0.000 description 1
210000003292 kidney cell Anatomy 0.000 description 1
230000002045 lasting effect Effects 0.000 description 1
239000007788 liquid Substances 0.000 description 1
229940083747 low-ceiling diuretics xanthine derivative Drugs 0.000 description 1
210000004698 lymphocyte Anatomy 0.000 description 1
238000012423 maintenance Methods 0.000 description 1
238000005259 measurement Methods 0.000 description 1
210000004379 membrane Anatomy 0.000 description 1
239000012528 membrane Substances 0.000 description 1
210000000663 muscle cell Anatomy 0.000 description 1
230000003472 neutralizing effect Effects 0.000 description 1
102000039446 nucleic acids Human genes 0.000 description 1
108020004707 nucleic acids Proteins 0.000 description 1
150000007523 nucleic acids Chemical class 0.000 description 1
210000000056 organ Anatomy 0.000 description 1
201000008968 osteosarcoma Diseases 0.000 description 1
239000002245 particle Substances 0.000 description 1
230000000144 pharmacologic effect Effects 0.000 description 1
230000007505 plaque formation Effects 0.000 description 1
229920001282 polysaccharide Polymers 0.000 description 1
239000005017 polysaccharide Substances 0.000 description 1
230000008569 process Effects 0.000 description 1
239000000047 product Substances 0.000 description 1
230000035755 proliferation Effects 0.000 description 1
230000005180 public health Effects 0.000 description 1
239000012264 purified product Substances 0.000 description 1
238000004445 quantitative analysis Methods 0.000 description 1
230000005855 radiation Effects 0.000 description 1
230000000717 retained effect Effects 0.000 description 1
150000003839 salts Chemical class 0.000 description 1
238000005070 sampling Methods 0.000 description 1
230000035945 sensitivity Effects 0.000 description 1
239000007858 starting material Substances 0.000 description 1
208000003265 stomatitis Diseases 0.000 description 1
229960004559 theobromine Drugs 0.000 description 1
229960000278 theophylline Drugs 0.000 description 1
230000001225 therapeutic effect Effects 0.000 description 1
238000004448 titration Methods 0.000 description 1
230000002792 vascular Effects 0.000 description 1
230000029812 viral genome replication Effects 0.000 description 1
230000003612 virological effect Effects 0.000 description 1
239000005723 virus inoculator Substances 0.000 description 1
239000011782 vitamin Substances 0.000 description 1
229940088594 vitamin Drugs 0.000 description 1
229930003231 vitamin Natural products 0.000 description 1
235000013343 vitamin Nutrition 0.000 description 1
229940075420 xanthine Drugs 0.000 description 1

Classifications

- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/52—Cytokines; Lymphokines; Interferons
- C07K14/555—Interferons [IFN]

Landscapes

Chemical & Material Sciences (AREA)
Health & Medical Sciences (AREA)
Life Sciences & Earth Sciences (AREA)
Organic Chemistry (AREA)
General Health & Medical Sciences (AREA)
Molecular Biology (AREA)
Biochemistry (AREA)
Biophysics (AREA)
Zoology (AREA)
Genetics & Genomics (AREA)
Medicinal Chemistry (AREA)
Gastroenterology & Hepatology (AREA)
Proteomics, Peptides & Aminoacids (AREA)
Toxicology (AREA)
Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Preparation Of Compounds By Using Micro-Organisms (AREA)
Micro-Organisms Or Cultivation Processes Thereof (AREA)
Peptides Or Proteins (AREA)
Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)

NL8120080A 1980-03-26 1981-03-25 Virusremmende stof en werkwijze voor de bereiding daarvan. NL8120080A (nl)

Applications Claiming Priority (4)

Application Number	Priority Date	Filing Date	Title
JP3749480A JPS56135420A (en)	1980-03-26	1980-03-26	Suppressive substance of virus and its preparation
JP3749480		1980-03-26
JP8100062		1981-03-25
PCT/JP1981/000062 WO1981002674A1 (fr)	1980-03-26	1981-03-25	Substance inhibant les virus et procede de preparation de celle-ci

Publications (1)

Publication Number	Publication Date
NL8120080A true NL8120080A (nl)	1982-02-01

Family

ID=12499069

Family Applications (1)

Application Number	Title	Priority Date	Filing Date
NL8120080A NL8120080A (nl)	1980-03-26	1981-03-25	Virusremmende stof en werkwijze voor de bereiding daarvan.

Country Status (9)

Country	Link
EP (1)	EP0048283B1 (de)
JP (1)	JPS56135420A (de)
AU (1)	AU538563B2 (de)
CH (1)	CH646875A5 (de)
DE (1)	DE3140623A1 (de)
GB (1)	GB2083359B (de)
NL (1)	NL8120080A (de)
SE (1)	SE8106944L (de)
WO (1)	WO1981002674A1 (de)

Families Citing this family (7)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
US4614651A (en) *	1981-07-12	1986-09-30	Damon Biotech, Inc.	Interferon epsilon
SE8303925L (sv) *	1982-07-12	1984-01-13	Damon Biotech Inc	Interferon e
US4675282A (en) *	1984-07-06	1987-06-23	Damon Biotech, Inc.	Assay for interferon epsilon
EP0278715A3 (de) *	1987-02-09	1989-03-08	Schering Corporation	Verwendung von menschlichem Gamma-Interferon für die Behandlung von Basalzell-Karzinomen
AU1319797A (en) *	1996-01-23	1997-08-20	Srl Inc.	Cells for treating dementia
SE513313C2 (sv) *	1998-12-29	2000-08-21	Bionative Ab	Modifierad interferonproduktion
TW200301132A (en) *	2001-12-06	2003-07-01	Sankyo Co	Pharmaceutical compositions containing cells derived from human caul

Family Cites Families (5)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
JPS5238009A (en) *	1975-09-19	1977-03-24	Green Cross Corp:The	Method for the manufacture of hige- activity prophylactic and therapeu tic agent for viral infections
JPS5251009A (en) *	1975-10-17	1977-04-23	Morinaga Milk Ind Co Ltd	Method of producing drug for treating marrow leukemia
CS215108B2 (en) *	1977-07-15	1982-07-30	Wellcome Found	Method of making the interferrone
JP3160997B2 (ja) *	1992-03-02	2001-04-25	セイコーエプソン株式会社	インクジェット式印字ヘッドおよびその製造方法
JPH05251009A (ja) *	1992-03-03	1993-09-28	Miyota Kk	インデクス・カラー陰極線管の蛍光膜

1980
- 1980-03-26 JP JP3749480A patent/JPS56135420A/ja active Pending
1981
- 1981-03-25 GB GB8135068A patent/GB2083359B/en not_active Expired
- 1981-03-25 WO PCT/JP1981/000062 patent/WO1981002674A1/ja not_active Ceased
- 1981-03-25 CH CH766981A patent/CH646875A5/de not_active IP Right Cessation
- 1981-03-25 AU AU69248/81A patent/AU538563B2/en not_active Ceased
- 1981-03-25 NL NL8120080A patent/NL8120080A/nl not_active Application Discontinuation
- 1981-03-25 DE DE813140623T patent/DE3140623A1/de not_active Withdrawn
- 1981-03-25 EP EP81900752A patent/EP0048283B1/de not_active Expired
- 1981-11-23 SE SE8106944A patent/SE8106944L/xx not_active Application Discontinuation

Also Published As

Publication number	Publication date
AU538563B2 (en)	1984-08-16
JPS56135420A (en)	1981-10-22
AU6924881A (en)	1981-10-09
CH646875A5 (de)	1984-12-28
EP0048283B1 (de)	1984-05-16
SE8106944L (sv)	1981-11-23
WO1981002674A1 (fr)	1981-10-01
EP0048283A1 (de)	1982-03-31
GB2083359A (en)	1982-03-24
GB2083359B (en)	1984-06-06
DE3140623A1 (de)	1982-04-29
EP0048283A4 (de)	1982-08-05

Legal Events

Date	Code	Title	Description
1985-01-01	A85	Still pending on 85-01-01
1988-05-02	BV	The patent application has lapsed

Publication	Publication Date	Title
NL192086C (nl)	1997-02-04	Werkwijze ter bereiding van interferonen en werkwijze ter bereiding van een geneesmiddel dat interferonen bevat.
JP3100005B2 (ja)	2000-10-16	ヒト免疫不全ウィルス感染・増殖抑制剤
FI60022B (fi)	1981-07-31	Foerfarande foer framstaellning av rent intravenoesdugligt gammaglobulin
Friedman et al.	1967	Stimulation of interferon production in human lymphocytes by mitogens
US4820514A (en)	1989-04-11	Low dosage of interferon to enhance vaccine efficiency
NL8000291A (nl)	1980-07-22	Werkwijze voor het bereiden van interferon type ii, de therapeutische toepassing van interferon type ii en de farmaceutische preparaten op basis hiervan.
JP4617058B2 (ja)	2011-01-19	コンセンサスインターフェロンのＢ型肝炎表面抗原とｅ抗原の抑制剤としての応用
US4460574A (en)	1984-07-17	Prophylaxis or treatment of interferon-sensitive diseases
JPS5813397A (ja)	1983-01-25	免疫インタ−フエロン及びそのｍＲＮＡの製造方法
FI72143C (fi)	1987-04-13	Foerfarande foer framstaellning av maenniskointerferon.
JP2005508848A6 (ja)	2005-08-04	コンセンサスインターフェロンのＢ型肝炎表面抗原とｅ抗原の抑制剤としての応用
MC1499A1 (fr)	1983-11-17	Interferon immun humain homogene et procede pour sa preparation
US4686284A (en)	1987-08-11	Production of monomeric human γ-interferon
EP0048283B1 (de)	1984-05-16	Virushemmende verbindung und verfahren zu deren herstellung
EP0027793A1 (de)	1981-05-06	Tierische interferone hoher reinheit
NO173144B (no)	1993-07-26	Fremgangsmaate til fremstilling av interferongamma
US4480032A (en)	1984-10-30	Natural mixture of Type I and Type II interferons
NL8302484A (nl)	1984-02-01	Interferon-preparaat en werkwijze voor de bereiding daarvan.
JP2005515266A (ja)	2005-05-26	免疫刺激剤として活性である植物抽出物
RU2051054C1 (ru)	1995-12-27	Способ получения препарата противогерпетического иммуноглобулина человека
US5714464A (en)	1998-02-03	Anti-viral mushroom extracts
Richmond	1969	An interferon-like inhibitor of foot-and-mouth disease virus induced by phytohemagglutinin in swine leukocyte culturesb
Henle et al.	1963	Differences in response of hamster tumor cells induced by polyoma virus to interfering virus and interferon
KR970002165B1 (ko)	1997-02-24	γ-인터페론의 제조방법과 그 용도
NL8401911A (nl)	1986-01-02	Antiviraal proteine, werkwijze voor het produceren daarvan, en farmaceutische preparaten die dit proteine bevatten.